Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?

被引：57

作者：

Hunt, Richard H. ^{[1
,2
]}

Scarpignato, Carmelo ^{[3
]}

机构：

[1] McMaster Univ, Dept Med, Div Gastroenterol, Hamilton, ON, Canada

[2] McMaster Univ, Dept Med, Farncombe Family Digest Hlth Res Inst, Hamilton, ON, Canada

[3] Univ Parma, Dept Clin & Expt Med, Clin Pharmacol & Digest Pathophysiol Unit, I-43100 Parma, Italy

来源：

CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY | 2015年 / 6卷

关键词：

PROTON PUMP INHIBITORS; NONEROSIVE REFLUX DISEASE; HELICOBACTER-PYLORI; DOUBLE-BLIND; UNMET NEEDS; TAK-438; VONOPRAZAN; DUAL THERAPY; MANAGEMENT; ERADICATION; SUPPRESSION;

D O I：

10.1038/ctg.2015.39

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The need for new acid suppressing agents with improved pharmacology and superior antisecretory effects to address unmet clinical needs in acid-related disorders has been evident for over a decade. Recent new antisecretory drugs (IR-omeprazole and MR-dexlansoprazole) only provide a small incremental advance in control of acid secretion over the delayed-release proton pump inhibitors. Vonoprazan (a new potassium-competitive acid blocker) displays more potent and extended 24 h acid suppression and preliminary Japanese trials translate this into meaningful clinical benefits in gastroesophageal reflux disease and Helicobacter pylori eradication. We review the vonoprazan information to date and the indications, benefits, and concerns of more effective therapeutic control of acid secretion.

引用

页数：4

共 46 条

[1] APPROPRIATE ACID SUPPRESSION FOR THE MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE [J].

BELL, NJV ;

BURGET, D ;

HOWDEN, CW ;

WILKINSON, J ;

HUNT, RH .

DIGESTION, 1992, 51 :59-67

[2] Patient and Physician Satisfaction with Proton Pump Inhibitors (PPIs): Are There Opportunities for Improvement? [J].

Chey, William D. ;

Mody, Reema R. ;

Izat, Esin .

DIGESTIVE DISEASES AND SCIENCES, 2010, 55 (12) :3415-3422

[3] A Randomized, Comparative Trial of a Potassium-Competitive Acid blocker (AZD0865)and Esomeprazole for the Treatment of Patients With Nonerosive Reflux Disease [J].

Dent, John ;

Kahrilas, Peter J. ;

Hatlebakk, Jan ;

Vakil, Nimish ;

Denison, Hans ;

Franzen, Stefan ;

Lundborg, Per .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (01) :20-26

[4] Unmet Needs in the Treatment of Gastroesophageal Reflux Disease [J].

Dickman, Ram ;

Maradey-Romero, Carla ;

Gingold-Belfer, Rachel ;

Fass, Ronnie .

JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2015, 21 (03) :309-319

[5] Management of heartburn not responding to proton pump inhibitors [J].

Fass, R. ;

Sifrim, D. .

GUT, 2009, 58 (02) :295-309

[6] Pharmacologic Aspects of Eradication Therapy for Helicobacter pylori Infection [J].

Furuta, Takahisa ;

Graham, David Y. .

GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2010, 39 (03) :465-+

[7] Control of 24-hour Intragastric Acidity With Morning Dosing of Immediate-release and Delayed-release Proton Pump Inhibitors in Patients With GERD [J].

Howden, Colin W. ;

Ballard, E. David ;

Koch, Frauke K. ;

Gautille, Theresa. C. ;

Bagin, Robert G. .

JOURNAL OF CLINICAL GASTROENTEROLOGY, 2009, 43 (04) :323-326

[8] A REVIEW OF THE STATUS OF OMEPRAZOLE - THE HANBURY WORKSHOP [J].

HUNT, R ;

SACHS, G .

DIGESTIVE DISEASES AND SCIENCES, 1995, 40 (02) :S1-S2

[9] Importance of pH control in the management of GERD [J].

Hunt, RH .

ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (07) :649-657

[10] The unmet needs in delayed-release proton-pump inhibitor therapy in 2005 [J].

Hunt, RH .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 22 :10-19

← 1 2 3 4 5 →